Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496782 · ClinicalTrials.gov registry record · Phase 1
Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay
A Phase 1 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00496782: Clinical Trial Phase 1 study, sponsored by ViiV Healthcare.
NCT00496782 is a Phase 1 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496782, a Phase 1 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to determine whether there is a correlation between viral load reduction (at Day 4, 7 or 14) following a short course (14 days) of Maraviroc added to a failing regimen, and the R5 result of the TrofileTM assay at screening.
Primary Outcome
Spearman's correlation coefficient to assess percentage of participants achieving HIV-1 RNA with tropism
Interventions
- DRUG maraviroc
- PROCEDURE Trofile Assay and HIV RNA quantification assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Why NCT00496782 stopped before completion
NCT00496782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which maraviroc is the first listed.
NCT00496782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00496782 about?
NCT00496782 is a clinical study titled "Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay". The purpose of this pilot study is to determine whether there is a correlation between viral load reduction (at Day 4, 7 or 14) following a short course (14 days) of Maraviroc added to a failing regimen, and the R5 result of the TrofileTM assay at screening.
What is the current status of trial NCT00496782?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-07. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00496782?
The interventions under investigation include: maraviroc (DRUG), Trofile Assay and HIV RNA quantification assay (PROCEDURE).
Who is sponsoring clinical trial NCT00496782?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00496782's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia